Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125508 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias
A Phase 2 study, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07125508 is a Phase 2 study that has completed, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 40 participants.
The verdict
NCT07125508, a Phase 2 study, has completed, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if oral tranexamic acid works to treat gastrointestinal angioectasias. It will also learn about the safety of tranexamic acid. The main questions it aims to answer are: Does tranexamic improve hemoglobin concentration and/or requirement for blood transfusions What medical problems do participants have when taking tranexamic acid? Researchers will compare tranexamic acid to a placebo (a look-alike substance that contains no drug) to see if it works to treat angioectasias. Participants will: Take tranexamic acid or a placebo three times per day, every day for 3 months Visit the clinic once per month for checkups and tests
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid (TXA) treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07125508
The ClinicalTrials.gov registry entry for NCT07125508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center in New Orleans, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07125508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07125508 about?
NCT07125508 is a clinical study titled "Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias". The goal of this clinical trial is to learn if oral tranexamic acid works to treat gastrointestinal angioectasias. It will also learn about the safety of tranexamic acid. The main questions it aims to answer are: Does tranexamic improve hemoglobin concentration and/or requirement for blood transfus...
What is the current status of trial NCT07125508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-08-01. Estimated completion is 2024-12-15.
What interventions are being tested in trial NCT07125508?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (TXA) treatment (DRUG).
Who is sponsoring clinical trial NCT07125508?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.